Premium
P4‐355: INTEGRATED BEHAVIORAL CARE ON INPATIENT MEDICAL UNITS: AN INNOVATIVE, NON‐PHARMACOLOGICAL APPROACH AND SYSTEMS CHANGE TO IMPROVE PATIENT OUTCOMES WITH DEMENTIA
Author(s) -
Sutherland Elizabeth S.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.07.179
Subject(s) - dementia , medicine , distress , complaint , health care , mental health , isolation (microbiology) , best practice , nursing , psychiatry , clinical psychology , disease , microbiology and biotechnology , pathology , political science , law , economics , biology , economic growth , management
CDR 0.5; n1⁄411), mild (MMSE 22-30, CDR 0.5-1; n1⁄414), or moderate (MMSE 16-21, CDR 0.5-2; n1⁄48) AD. [F]GTP1 SUVR was measured in a meta-ROI that included the amygdala and the entorhinal, parahippocampal, fusiform, inferior temporal, and middle temporal cortices, using the cerebellar gray as reference. Results: Across the entire cohort, Spearman correlation analyses demonstrated associations between baseline [F]GTP1 SUVR and 12month longitudinal change on the MMSE (rs1⁄4-0.56, p<0.001), ADAS-Cog13 (rs1⁄40.63, p<0.001), RBANS z-score (rs1⁄4-0.49, p1⁄40.002), and CDR-SB (rs1⁄40.39, p1⁄40.011). These prognostic associations were primarily driven by the prodromal and mild AD cohorts, particularly on the ADAS-Cog13 (prodromal: rs1⁄40.69; mild: rs1⁄40.66) and RBANS z-score (prodromal: rs1⁄4-0.28; mild: rs1⁄40.54). After adjustments for baseline age and MMSE scores, baseline [F]GTP1 SUVR in the combined prodromal and mild AD groups continued to correlate with longitudinal decline on the ADAS-Cog13 (p1⁄40.005) and RBANS z-score (p1⁄40.008) Conclusions:These preliminary results confirm and extend prior findings suggesting the utility of tau PET signal in the temporal lobe as a prognostic biomarker in AD, particularly for prodromal and mild AD. More specific ROIs may yield further prognostic value at different stages of disease progression or for decline in individual cognitive domains.